Learn About Denys-Drash Syndrome (DDS)
Denys-Drash syndrome is a condition that affects the kidneys and genitalia.
Mutations in the WT1 gene cause Denys-Drash syndrome. The WT1 gene provides instructions for making a protein that regulates the activity of other genes by attaching (binding) to specific regions of DNA. On the basis of this action, the WT1 protein is called a transcription factor. The WT1 protein plays a role in the development of the kidneys and gonads (ovaries in females and testes in males) before birth.
The prevalence of Denys-Drash syndrome is unknown; at least 150 affected individuals have been reported in the scientific literature.
This condition is inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder.
Sorahia Domenice practices in Sao Paulo, Brazil. Domenice is rated as an Elite expert by MediFind in the treatment of Denys-Drash Syndrome (DDS). Their top areas of expertise are Intersex, Denys-Drash Syndrome (DDS), Partial Androgen Insensitivity Syndrome (PAIS), Turner Syndrome, and Hormone Replacement Therapy (HRT).
Kentaro Nishi practices in Tokyo, Japan. Mr. Nishi is rated as an Elite expert by MediFind in the treatment of Denys-Drash Syndrome (DDS). His top areas of expertise are Denys-Drash Syndrome (DDS), Nephrotic Syndrome, Congenital Nephrotic Syndrome, Nephrectomy, and Small Bowel Resection.
Atrium Health Levine Children’s Cancer & Blood Disorders, A Facility Of Carolinas Medical Center
Joel Kaplan is a Hematologist and a Pediatrics provider in Charlotte, North Carolina. Dr. Kaplan has been practicing medicine for over 24 years and is rated as an Advanced provider by MediFind in the treatment of Denys-Drash Syndrome (DDS). His top areas of expertise are Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Medulloblastoma, Langerhans Cell Histiocytosis, and Bone Marrow Aspiration. Dr. Kaplan is currently accepting new patients.
Summary: The study is based on results form 2 previous studies carried out by the GFAOP. The aim of this study is to evaluate the capacity of units to follow the recommendations in the protocol.
Summary: This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Drugs used in chemotherapy regimens such as UH-3 (vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan) and ICE/Cyclo/Topo (ifosfamide...
Published Date: March 01, 2013
Published By: National Institutes of Health